Keywords: study, results, suggest, b-ms/ostuka, abilify, safe, long-term
Study results suggest B-MS/Ostuka's Abilify is safe for long-term schizophrenia combination therapy
Article | 06 April 2009
Bristol-Myers Squibb and Otsuka Pharmaceuticals' Abilify (aripiprazole), in combination with lithium or valproate, is safe as a long-term treatment for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
